Nasal septum perforation and bevacizumab
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The use of targeted/biologic therapies is now commonplace in the treatment of malignant and non-malignant diseases. The novel mode of action of these drugs has resulted in unpredictable and in some cases unexpected side effects. Given the widespread use of bevacizumab and its distinct mode of action, it is important that oncologists report any unexpected adverse events that may be associated with the drug. Herein, we report three cases of spontaneous nasal septum perforation secondary to bevacizumab. We hypothesize an etiology for this rare event and reasons why it is reasonable to rechallenge the patient.
- Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219–28. CrossRef
- LoRusso P. Toward evidence-based management of the dermatologic effects of EGFR inhibitors. Oncology (Williston Park). 2009;23:186–94.
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6. CrossRef
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76. CrossRef
- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42. CrossRef
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50. CrossRef
- Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72. CrossRef
- Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131–8. CrossRef
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11. CrossRef
- Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180–6. CrossRef
- Van den Wyngaert T, Huizing MT, Fossion E, et al. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist. 2009;14:181–91. CrossRef
- Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. 2009;169:1976–85. CrossRef
- Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361:1081–7. CrossRef
- Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Engl J Med. 2008;358:1109–17. CrossRef
- Genentech: http://www.gene.com/gene/products/information/oncology/avastin/ (2009). Accessed Nov 26th 2009.
- Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10:559–68. CrossRef
- Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43:490–501. CrossRef
- Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821–6. CrossRef
- Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70. CrossRef
- van Heeckeren WJ, Ortiz J, Cooney MM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007;25:2993–5. CrossRef
- Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–2. Discussion 980–2. CrossRef
- Bhattacharyya N. Clinical symptomatology and paranasal sinus involvement with nasal septal perforation. Laryngoscope. 2007;117:691–4. CrossRef
- Diamantopoulos, II, Jones NS. The investigation of nasal septal perforations and ulcers. J Laryngol Otol. 2001;115:541–4.
- Lee SL, Neskey D, Mouzakes J. Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review. Ear Nose Throat J. 2009;88:E12–4.
- Tan TH, Stevenson B, Yip D. Docetaxel-induced nasal septal perforation. Intern Med J. 2006;36:471–2. CrossRef
- Burkart CM, Grisel JJ, Hom DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008;118:1539–41. CrossRef
- Marin AP, Sanchez AR, Arranz EE. Nasal septum perforation in a breast cancer patient treated with bevacizumab. Ann Oncol. 2009;20:1901–2. CrossRef
- Ruiz N, Fernandez-Martos C, Romero I, et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007;25:3376–7. CrossRef
- Traina TA, Norton L, Drucker K, et al. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist. 2006;11:1070–1. CrossRef
- Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist. 2006;11:85–6. CrossRef
- Nasal septum perforation and bevacizumab
Volume 28, Issue 1 , pp 89-93
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Colorectal cancer
- Breast cancer
- Ovarian cancer
- Nasal septum perforation
- Targeted therapy
- Industry Sectors